Shandong Suncadia Medicine Co., Ltd.
suncadia.comTotal trials
77
Active
40
Phase 3
11
Total enrollment
18,652
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 63 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| HRS-7535 | — | — | — | 16 | |||
| HRS-1893 | — | — | — | 8 | |||
| HRS-8080 | — | — | — | 6 | |||
| HRS-2129 | — | — | — | 6 | |||
| HRS-7058 | — | — | — | — | 3 | ||
| Letrozole | — | — | — | — | 3 | ||
| HRS-1780 | — | — | — | 4 | |||
| Tramadol Hydrochloride SR | — | — | — | — | 2 | ||
| Fulvestrant | — | — | — | — | 2 | ||
| HRS-1893 Placebo | — | — | — | — | 2 | ||
| Anastrozole | — | — | — | — | — | 2 | |
| Exemestane | — | — | — | — | — | 2 | |
| HRS-7535 placebo | — | — | — | — | — | 2 | |
| Tamoxifen Citrate | — | — | — | — | — | 1 | |
| Fulzerasib | — | — | — | — | — | 1 | |
| Garsorasib | — | — | — | — | — | 1 | |
| Glecirasib Citrate | — | — | — | — | — | 1 | |
| Blank Preparation. | — | — | — | — | — | 1 | |
| HRS-8080 Tablet ; Dalpiciclib Isethionate | — | — | — | — | — | 1 | |
| Fulvestrant injection ;Dalpiciclib Isethionate | — | — | — | — | — | 1 | |
| dapagliflozin | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| HRS-2129 Placebo | — | — | — | — | 4 | ||
| HRS-1301 | — | — | — | — | 4 | ||
| HRS-1358 | — | — | — | — | 2 | ||
| HRS-6208 | — | — | — | — | 2 | ||
| HRS-6209 | — | — | — | — | — | 2 | |
| HRS-2189 | — | — | — | — | 2 | ||
| HRS-7085 | — | — | — | — | 2 | ||
| HRS-7058 + SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy | — | — | — | — | — | 1 | |
| HRS-7058 + Cetuximab | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-1826 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-1826 + SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-A1202 | — | — | — | — | — | 1 | |
| HRS-7058 + BP102 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-9839 | — | — | — | — | — | 1 | |
| HRS-7058 +SHR-A2102 +SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 +SHR-9839(sc)+SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 +SHR-1316 +BP102 | — | — | — | — | — | 1 |
23 more active programs hidden
Next readouts
- 2024-10-30
- 2024-11-18
- 2025-05-30
- 2025-06
- 2025-08
- 2025-12
- 2026-01
- 2026-02-18
- 2026-03
- 2026-05
Top conditions
- Type 2 Diabetes7
- Breast Cancer6
- Chronic Kidney Disease4
- Obstructive Hypertrophic Cardiomyopathy4
- Type 2 Diabetes Mellitus4
- Hyperlipidemia3
- Advanced Malignant Tumour2
- Cardiomyopathy2
Frequently asked questions about Shandong Suncadia Medicine Co., Ltd.
- How many clinical trials does Shandong Suncadia Medicine Co., Ltd. have on ClinicalTrials.gov?
- Shandong Suncadia Medicine Co., Ltd. is listed as the lead sponsor on 77 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shandong Suncadia Medicine Co., Ltd.'s trials are in Phase 3?
- 11 of Shandong Suncadia Medicine Co., Ltd.'s trials are in Phase 3, spread across 63 active drug programs.
- What therapeutic areas does Shandong Suncadia Medicine Co., Ltd. focus on?
- Shandong Suncadia Medicine Co., Ltd.'s most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Breast Cancer, Chronic Kidney Disease, Obstructive Hypertrophic Cardiomyopathy, Type 2 Diabetes Mellitus.
- When are Shandong Suncadia Medicine Co., Ltd.'s next clinical trial readouts?
- Shandong Suncadia Medicine Co., Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase 1, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects”, expected around 2024-10-30.